He has over 15 year’s research experience in human natural killer (NK) cell biology and infection. Dr Goodier’s research focusses on the impact of genetic and environmental factors on the functional differentiation of natural killer cells in children and adults. His research findings demonstrate important geographical differences in NK cell function in UK and African settings and the influence of regional genetic differences and exposure to human cytomegalovirus. Dr Goodier’s recent work unravels the relationship between acquired immune responses and the activation of NK cells after vaccination and the generation of memory-like NK cells after seasonal influenza and DTPiP vaccinations. As a member of the EBOVAC consortium, he is currently investigating the potential of EBOLA vaccine to promote NK cell responses in clinical trials.